Annual reports in medicinal chemistry

• 

  Año 2013, Número 48

  • Chapter One - Challenges in Drug Discovery at Schering–Plough Research Institute: A Personal Reflection

    A.K. Ganguly

    • Resumen

    págs. 3-14

    

  • Chapter Two - My Perspective on Time, Managers—and Scientific Fun

    Christopher A. Lipinski

    págs. 15-22

    

  • Chapter Three - A Career in Medicinal Chemistry—A Journey in Drug Discovery

    Malcolm MacCoss

    • Resumen

    págs. 23-34

    

  • Chapter Four - Selective Inhibitors of PDE2, PDE9, and PDE10: Modulators of Activity of the Central Nervous System

    Morten Jørgensen, Jan Kehler, Morten Langgård, Niels Svenstrup, Lena Tagmose

    • Resumen

    págs. 37-55

    

  • Chapter Five - Beyond Secretases: Kinase Inhibitors for the Treatment of Alzheimer’s Disease

    Federico Medda, Breland Smith, Vijay Gokhale, Arthur Y. Shaw, Travis Dunckley, Christopher Hulme

    • Resumen

    págs. 57-71

    

  • Chapter Six - Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders

    Scott D. Kuduk, Christopher J. Winrow, Paul J. Coleman

    • Resumen

    págs. 73-87

    

  • Chapter Seven - Discovery and Development of Prolylcarboxypeptidase Inhibitors for Cardiometabolic Disorders

    Sarah Chajkowski Scarry, John M. Rimoldi

    • Resumen

    págs. 91-103

    

  • Chapter Eight - Molecular Targeting of Imaging and Drug Delivery Probes in Atherosclerosis

    Cesare Casagrande, Daniela Arosio, Claudia Kusmic, Leonardo Manzoni, Luca Menichetti, Antonio L’Abbate

    • Resumen

    págs. 105-118

    

  • Chapter Nine - Oral GLP-1 Modulators for the Treatment of Diabetes

    David J. Edmonds, David A. Price

    • Resumen

    págs. 119-130

    

  • Chapter Ten - Recent Advances in the Discovery and Development of CCR1 Antagonists

    Penglie Zhang, Daniel J. Dairaghi, Juan C. Jaen, Jay P. Powers

    • Resumen

    págs. 133-147

    

  • Chapter Eleven - Emerging Targets for the Treatment of Idiopathic Pulmonary Fibrosis

    Matthew C. Lucas, David C. Budd

    • Resumen

    págs. 149-167

    

  • Chapter Twelve - Targeting the Nuclear Hormone Receptor RORγt for the Treatment of Autoimmune and Inflammatory Disorders

    T. G. Murali Dhar, Qihong Zhao, David W. Markby

    • Resumen

    págs. 169-182

    

  • Chapter Thirteen - Recent Advances in Small-Molecule Modulation of Epigenetic Targets: Discovery and Development of Histone Methyltransferase and Bromodomain Inhibitors

    Ramzi F. Sweis, Michael R. Michaelides

    • Resumen

    págs. 185-203

    

  • Chapter Fourteen - Inhibition of Ubiquitin Proteasome System Enzymes for Anticancer Therapy

    David Wustrow, Han-Jie Zhou, Mark Rolfe

    • Resumen

    págs. 205-225

    

  • Chapter Fifteen - Targeting Protein–Protein Interactions to Treat Cancer—Recent Progress and Future Directions

    William Garland, Robert Benezra, Jaideep Chaudhary

    • Resumen

    págs. 227-245

    

  • Chapter Sixteen - Recent Progress in the Discovery of Neuraminidase Inhibitors as Anti-influenza Agents

    Aisyah Saad Abdul Rahim, Mark von Itzstein

    • Resumen

    págs. 249-263

    

  • Chapter Seventeen - Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection

    Yimin Hu, Wei Zhu, Guozhi Tang, Alexander V. Mayweg, Guang Yang, Jim Z. Wu, Hong C. Shen

    • Resumen

    págs. 265-281

    

  • Chapter Eighteen - Special Challenges to the Rational Design of Antibacterial Agents

    Kirk E. Hevener, Shuyi Cao, Tian Zhu, Pin-Chih Su, Shahila Mehboob, Michael E. Johnson

    • Resumen

    págs. 283-298

    

  • Chapter Nineteen - Recent Advances in Small Molecule Target Identification Methods

    Rohan E.J. Beckwith, Rishi K. Jain

    • Resumen

    págs. 301-315

    

  • Neuroinflammation in Mood Disorders: Mechanisms and Drug Targets

    Allent T. Hopper, Kenneth A. Jones, Brian M. Campbell, Guiying Li

    • Resumen

    págs. 317-331

    

  • Chapter Twenty-One - Inhibitors of hERG Channel Trafficking: A Cryptic Mechanism for QT Prolongation

    Kap-Sun Yeung, Nicholas A. Meanwell

    • Resumen

    págs. 335-352

    

  • Chapter Twenty-Two - Recent Progress in Small-Molecule Agents Against Age-Related Macular Degeneration

    Muneto Mogi, Christopher M. Adams, Nan Ji, Nello Mainolfi

    • Resumen

    págs. 353-369

    

  • Chapter Twenty-Three - Synthetic Macrocycles in Small-Molecule Drug Discovery

    Sandrine Vendeville, Maxwell D. Cummings

    • Resumen

    págs. 371-386

    

  • Chapter Twenty-Four - Glossary of Terms Used in Medicinal Chemistry Part II (IUPAC Recommendations 2013)

    Derek R. Buckle, P.W. Erhardt, C.R. Ganellin, Toshi Kobayashi, Thomas J. Perun, John Proudfoot, Joerg Senn-Bilfinger

    • Resumen

    págs. 387-418

    

  • Chapter Twenty-Five - Case History: Xalkori™ (Crizotinib), a Potent and Selective Dual Inhibitor of Mesenchymal Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) for Cancer Treatment

    J. Jean Cui, Michele McTigue, Robert Kania, Martin Edwards

    • Resumen

    págs. 421-434

    

  • Chapter Twenty-Six - Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma

    Prabha N. Ibrahim, Jiazhong Zhang, Chao Zhang, Gideon Bollag

    • Resumen

    págs. 435-449

    

  • Chapter Twenty-Seven - New Chemical Entities Entering Phase III Trials in 2012

    Gregory T. Notte

    • Resumen

    págs. 451-469

    

  • Chapter Twenty-Eight - To Market, To Market—2012

    Joanne Bronson, Amelia Black, T. G. Murali Dhar, Bruce A. Ellsworth, J. Robert Merritt

    • Resumen

    págs. 471-546

    

  • Keyword Index, Volume 48

    págs. 547-553

    

  • Cumulative JOURter Titles Keyword Index, Volume 1 – 48

    págs. 555-577